About: Antibodies to an Interfering Epitope in Hepatitis C Virus E2 Can Mask Vaccine-Induced Neutralizing Activity

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Antibodies to an Interfering Epitope in Hepatitis C Virus E2 Can Mask Vaccine-Induced Neutralizing Activity Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Antibodies to an Interfering Epitope in Hepatitis C Virus E2 Can Mask Vaccine-Induced Neutralizing Activity
Creator	Zhang, Pei Kachko, Alla Ray, Ranjit Sirota, Lev Wells, Frances Zubkova, Iryna Frey, Sharon Major, Marian
Source	Medline; PMC
abstract	Hepatitis C virus (HCV) neutralization occurring at the E2 region 412–426 (EP-I) could be enhanced when antibodies directed specifically to the E2 region 434–446 (EP-II) were removed from serum samples of persistently infected patients and vaccinated chimpanzees, a phenomenon of so-called antibody interference. Here we show that this type of interference can be observed in individuals after immunization with recombinant E1E2 proteins. One hundred and twelve blinded serum samples from a Phase I, placebo-controlled, dose escalation trial using recombinant HCV E1E2 with MF59C.1 adjuvant in healthy HCV-negative adults were tested in ELISA for binding reactivity to peptides representing the E2 regions 412–426 (EP-I) and 434–446 (EP-II). All samples were subsequently tested for neutralizing activity using HCVcc 1a(H77)/2a chimera, HCVpp H77 and HCVpp HCV-1 after treatment to remove EP-II-specific antibodies or mock treatment with a control peptide. Among the 112 serum samples we found 22 double positive (EP-I and EP-II), 6 EP-II positive only, 14 EP-I positive only and 70 double negative. Depleting EP-II antibodies from double positive serum samples increased ID(50) neutralizing antibody titers (up to 4.9-fold) in up to 72% of samples (p≤0.0005) contrasting with ID(50) neutralization titer increases in 2 of 70 double negative samples (2.9%) (p>0.5). In addition, EP-I-specific antibody levels in serum samples showed a significant correlation with ID(50) neutralization titers when EP-II antibodies were removed (p<0.0003). CONCLUSION: These data show that antibodies to the region 434–446 are induced during immunization of individuals with recombinant E1E2 proteins and that these antibodies can mask effective neutralizing activity from EP-I-specific antibodies. Elicitation of EP-II-specific antibodies with interfering capacity should be avoided in producing an effective cross-neutralizing vaccine aimed at the HCV envelope proteins.
has issue date	2015-10-16(xsd:dateTime)
bibo:doi	10.1002/hep.28108
bibo:pmid	26251214
has license	bronze-oa
sha1sum (hex)	6565f5a0d6c858411d2c234fc1aaa0deb8cad13c
schema:url	https://doi.org/10.1002/hep.28108
resource representing a document's title	Antibodies to an Interfering Epitope in Hepatitis C Virus E2 Can Mask Vaccine-Induced Neutralizing Activity
has PubMed Central identifier	PMC4681649
has PubMed identifier	26251214
schema:publication	Hepatology
resource representing a document's body	covid:6565f5a0d6c858411d2c234fc1aaa0deb8cad13c#body_text
is schema:about of	named entity 'serum' named entity 'binding' named entity 'dose' named entity 'antibodies' named entity 'neutralizing' named entity 'optical density' named entity 'enzyme-linked immunosorbent assay' named entity 'escalation' named entity 'activity' named entity 'activity' named entity 'Epitope' named entity 'INTERFERING' named entity 'PLACEBO-CONTROLLED' named entity 'HVR1' named entity 'HERE' named entity 'IMMUNIZATION' named entity 'BLINDED' named entity 'FOUND' named entity 'SPECIFIC' named entity 'PATIENTS' named entity 'AFTER TREATMENT' named entity 'NEUTRALIZING ANTIBODY' named entity 'TITER' named entity 'AMINO ACID' named entity 'FORMING' named entity 'HEPATITIS C VIRUS' named entity 'RECOMBINANT' named entity 'THESE' named entity 'CONTRASTING' named entity 'ENZYME-LINKED IMMUNOSORBENT ASSAY' named entity 'particles' named entity 'HIV' named entity 'monoclonal antibodies' named entity 'positive' named entity 'tested' named entity 'Abbreviations' named entity 'serum' named entity 'All' named entity 'recombinant' named entity 'control' named entity 'antibodies' named entity 'avoided' named entity 'Conclusion' named entity 'antibody' named entity 'serum' named entity 'luciferase' named entity 'proteins' named entity 'double' named entity 'levels' named entity 'vaccinated' named entity 'neutralization' named entity 'Antibodies' named entity 'envelope proteins' named entity 'titer' named entity 'amino acid' named entity 'antibodies' named entity 'monoclonal antibodies' named entity 'peptides' named entity 'HCV' named entity 'correlation' named entity 'HIV' named entity 'enzyme-linked immunosorbent assay' named entity 'phosphate-buffered saline' named entity 'peptide' named entity 'antibodies' named entity 'Vaccine' named entity 'Epitope' named entity 'positive' named entity 'regions' named entity '5.0' named entity 'dose-escalation' named entity 'HCV' named entity 'neutralizing antibodies' named entity 'peptide'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software